Kailera Therapeutics: Ownership Change Reported
Ticker: KLRA · Form: 4 · Filed: Apr 20, 2026 · CIK: 0002096997
Sentiment: neutral
Topics: insider-filing, ownership-change
TL;DR
Kailera ownership change filed. Insider activity.
AI Summary
On April 16, 2026, Paul D. Burgess, a reporting person associated with Translate Bio, Inc., reported a change in beneficial ownership of securities related to Kailera Therapeutics, Inc. The filing details transactions that occurred on this date, but specific details regarding the nature of the transactions, the number of shares, or dollar amounts are not provided in this excerpt.
Why It Matters
This filing indicates a change in the beneficial ownership of Kailera Therapeutics, Inc. securities, which could signal insider activity or shifts in holdings.
Risk Assessment
Risk Level: low — The filing is a standard Form 4 reporting ownership changes, with no immediate indication of significant financial risk.
Key Players & Entities
- Kailera Therapeutics, Inc. (company) — Issuer
- Paul D. Burgess (person) — Reporting Person
- Translate Bio, Inc. (company) — Associated Company
FAQ
What was the period of report for this Form 4 filing?
The period of report was April 16, 2026.
Who is the reporting person associated with this filing?
Paul D. Burgess is the reporting person.
What is the CIK for Kailera Therapeutics, Inc.?
The CIK for Kailera Therapeutics, Inc. is 0002096997.
What is the business address for Kailera Therapeutics, Inc.?
The business address for Kailera Therapeutics, Inc. is 180 THIRD AVENUE 4TH FLOOR WALTHAM MA 02451.
What SIC code is listed for Kailera Therapeutics, Inc.?
The SIC code listed is 2834 for Pharmaceutical Preparations.
Filing Details
This Statement of Changes in Beneficial Ownership (Form 4) was filed with the SEC on April 20, 2026 by Paul D. Burgess regarding Kailera Therapeutics, Inc. (KLRA). Form 4 filings disclose purchases, sales, or other changes in ownership by company insiders such as officers, directors, and major shareholders.